Latest data from the Hong Kong Stock Exchange shows that on December 22, a shareholder of MP CARDIOFLOW-B (02160) deposited shares in Bank of China (Hong Kong), with a market value of HK$360 million, representing 5.23% of holdings.

MP CARDIOFLOW-B announced the following board changes effective December 15, 2025: Non-executive Director and Board Chairman Mr. Chen Guoming has been appointed as a member of the Audit Committee and will no longer serve on the Remuneration Committee or as Chairman of the Nomination Committee. Independent Non-executive Director Dr. Hu Bingshan has been reassigned as Chairman of the Nomination Committee and appointed to the Remuneration Committee, while stepping down from the Audit Committee. Non-executive Director Dr. Brian Chang has joined the Nomination Committee.

The Board resolved to establish a Strategic Committee under its governance, effective December 15, 2025. This committee will research and propose recommendations regarding the company's long-term development strategies and major decisions. The six-member committee includes Dr. Brian Chang, Mr. Chen Guoming, Mr. Zhang Ruinian, Mr. Philippe Wanstok, Mr. Deng Aoyi, and Dr. Hu Bingshan, with Dr. Brian Chang serving as Chairman.

Additionally, the Board approved the formation of a Commercialization Committee, also effective December 15, 2025. This committee aims to optimize planning and execution of the company's commercialization system, enhance market competitiveness of products during commercialization phases. The five-member committee comprises Mr. Chen Guoming, Dr. Brian Chang, Mr. Zhang Ruinian, Mr. Philippe Wanstok, and Ms. Wu Xia, with Mr. Chen Guoming as Chairman.